Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $55.25 | Total: $276.25 |
| 1 | 10 | $46.80 | Total: $468.00 |
| 1 | 25 | $39.65 | Total: $991.25 |
| 1 | 50 | $33.80 | Total: $1,690.00 |
| 1 | 100 | $29.25 | Total: $2,925.00 |
Overview
ASTX660 is an orally bioavailable dual antagonist of cIAP (cellular inhibitor of apoptosis protein) and XIAP (X-linked inhibitor of apoptosis protein).
Chemical Properties
| Molecular Formula | C30H42FN5O3 |
| Molecular Weight | 539.68 |
| CAS Numbers | 1799328-86-1 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | C[C@@H]1CN(CC(=O)N2CC(C)(C)c3nc(CO)c(Cc4ccc(F)cc4)cc23)[C@@H](CN2CCOC[C@H]2C)CN1 |
Storage and Handling
0C Short Term, -20C Long Term
References
Tomoko Smyth, et al. Abstract 1287 The dual IAP antagonist, ASTX660, increases the anti-tumor activity of paclitaxel in preclinical models of triple-negative breast cancer in vivo. Cancer Res 2016;76[14 Suppl].